What is Moderna?
Moderna, Inc. is a biotechnology company based in Cambridge, Massachusetts that develops mRNA-based therapeutics and vaccines. Its recent public commentary has centered on cancer programs, particularly an mRNA-based individualized therapy for melanoma, and on the speed and immunology of its mRNA platform.
Company timeline
- Sep 2026 - Stéphane Bancel said the needle-to-needle time for Moderna’s individualized cancer therapy is now around 42 days.
- Sep 2026 - Bancel said roughly 80% of patients were disease free five years after treatment.
- Sep 2026 - Bancel said the melanoma trial met its secondary endpoint of distant metastasis-free survival, a result he called a surprise even to Moderna.
- Sep 2026 - Bancel said the trial showed, for the first time, an agent in melanoma better than Keytruda alone.
- Sep 2026 - Bancel said de novo T cells are created that recognize what Moderna codes in the mRNA, which was not in the patient’s body before treatment.
- Sep 2026 - Bancel said Moderna announced in spring 2026 a Phase 3 study in stage one lung cancer using the product as a monotherapy, and that about 90% of antigens differ from one person to another.
Where it appears in the record
Every line below is attributed to a named speaker.
Moderna's personalized cancer vaccine manufacturing cycle is currently 42 days from tumor biopsy to vaccine delivery at the hospital.
“The time is around 42 days now needle to needle.”Stéphane Bancel · 2 Sep 2026
Around 80% of patients in Moderna's Phase 2 melanoma trial were disease-free five years after treatment with the mRNA cancer vaccine plus pembrolizumab.
“You had around 80% of people that were disease free five years after their treatment.”Stéphane Bancel · 2 Sep 2026
Moderna's mRNA cancer vaccine works by generating entirely new T cells in the patient that specifically recognize tumor neoantigens encoded in the mRNA, T cells that did not exist in the body before treatment.
“We have denovo new tea cells being created that recognize what we code in the mRNA that was not in the patient's body before the treatment.”Stéphane Bancel · 2 Sep 2026
Stéphane Bancel on the mRNA cancer vaccine beating Keytruda alone in melanoma.
“It's a first time that there is an agent in melanoma that is better than kudra alone.”Stéphane Bancel · 2 Sep 2026
The Phase 3 melanoma trial's distant metastasis-free survival secondary endpoint was met at the first interim analysis, an outcome that surprised even Moderna's own team.
“What was a surprise even to us is we met the secondary endpoint which was distant metastasis free survival.”Stéphane Bancel · 2 Sep 2026
Moderna's personalized cancer vaccine Intaran is expected to be regulated under a process BLA rather than a product BLA, a novel regulatory model in which the FDA approves the manufacturing process itself rather than individual product batches.
“We believe Intaran will be which is as a process BLA not a product BLA.”Stéphane Bancel · 2 Sep 2026
90% of tumor neoantigens selected for Moderna's personalized cancer vaccines are unique to each individual patient and not shared across patients.
“Actually 90% of antigen are different from a human to another one.”Stéphane Bancel · 2 Sep 2026
Moderna launched a Phase 3 trial for Stage 1 lung cancer using its mRNA cancer vaccine as a monotherapy, without combining it with checkpoint inhibitors, a departure from the combination approach used in melanoma.
“We announced in the spring of 2026 starting a phase three study for patient with stage one lung cancer. But as in so modernized product as a monotherapy.”Stéphane Bancel · 2 Sep 2026
Rahm Emanuel on Chinese leaders quietly taking Western COVID vaccines instead of the domestic one.
“We know for a fact that a lot of Chinese leaders were not taking the Chinese vaccine but they were end up taking quietly fizer madna etc.”Rahm Emanuel · 13 Aug 2026